A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania
The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Abstract
Background: Evidence synthesis methods enabling direct and indirect comparisons over the entire set of relevant clinical data produce quantitative point estimates for the treatments contrasts between competing interventions, and provide a hierarchical rank ordering between them. We aimed to provide evidence-based guidance on the efficacy and all-cause discontinuation of antimanic treatments. Method: We conducted a network meta-analysis within a Bayesian framework. We searched all standard literature databases without language restrictions up to 15 January 2014 to identify reports of short-term, randomized, blinded trials of putative antimanic drugs as monotherapy for adults with bipolar-I mania. Results: Altogether, 14256 manic patients randomized to one of 18 active treatments or placebo provided 95 direct comparisons on 128 data points. For the primary outcome, standardized mean difference as Hedges’ g (standardized mean difference; SMD), the hierarchies indicated by surface under the cumulative ranking (SUCRA) probabilities were in agreement with the point estimates for all antimanic drugs identified as effective. For the 12 effective antimanic drugs on clinical use, SMDs against placebo ranged from 0.32 to 0.66 without superiority of one over another, except for risperidone v . aripiprazole and valproate. Aripiprazole, olanzapine, quetiapine, risperidone, and valproate had less all-cause discontinuation rates than placebo. Sensitivity analysis by drug class indicated similar efficacy profiles for haloperidol, second-generation antipsychotics, and mood stabilizers. Conclusions: Hierarchical rank ordering by comparative efficacy and risk of all-cause discontinuations should help to guide antimanic treatment choices by clinicians, healthcare policy makers, and guideline developers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, these agents show comparable efficacy (Cohen's d 0.32‐0.66; small to medium effect size).143”
In the citing paper
“In patients who are inadequately responsive to first‐line agents, second‐line choices include monotherapy with olanzapine (level 1), carbamazepine (level 1), ziprasidone (level 1), and haloperidol (level 1)143 or combination therapy with olanzapine plus lithium or divalproex (level 1).”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 1×
“…Mania Rating Scale (YMRS; 11 items, scoring range: 0–60) or the Mania Rating Scale developed from the Schedule for Affective Disorders and Schizophrenia, Change Version (MRS; 11 items, range: 0–53), as change in total score from baseline to endpoint (Endicott & Spitzer, 1978; Young et al. 1978).”
MethodResearch Diagnostic Criteria: Rationale and Reliability
Spitzer, R. L. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770300115013 · Cited by 6,951 · cited 3×
“However, the network was quite homogeneous, with a trial duration of 3 or 4 weeks in 94%, and employment of recent DSM diagnostic criteria in 98% of trials; unreported allocation concealment or unfair dose comparisons being identified in only 9% and 4% of the included RCTs, respectively (Spitzer et al. 1978; APA, 2000…”
BackgroundMethodA Diagnostic Interview: The Schedule for Affective Disorders and Schizophrenia
Endicott, J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770310043002 · Cited by 5,684 · cited 1×
“…Mania Rating Scale (YMRS; 11 items, scoring range: 0–60) or the Mania Rating Scale developed from the Schedule for Affective Disorders and Schizophrenia, Change Version (MRS; 11 items, range: 0–53), as change in total score from baseline to endpoint (Endicott & Spitzer, 1978; Young et al. 1978).”
MethodSalanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766 · cited 4×
“…small changes in the posterior distribution of effect sizes (either the mean or the variance), and high probabilities in low ranks do not necessarily indicate the most effective treatments (Salanti et al. 2011), we provided effect sizes of pairwise comparisons, along with measures on probabilities.”
BackgroundMethodInfluential(1984) · The Lancet · doi:10.1016/s0140-6736(84)92810-1 · Cited by 2,925
Subgenual prefrontal cortex abnormalities in mood disorders
Drevets, W. C., Price, J. L., Simpson, J. R., Todd, R. D., Reich, T., Vannier, M., & Raichle, M. E. (1997) · Nature · doi:10.1038/386824a0 · Cited by 2,693 · cited 2×
“…and lithium or valproate, one may visualize how ranking by efficacy may be challenged by other sources of evidence as for detrimental effects of haloperidol in brain in contrast to lithium or valproate (Drevets et al. 1997; Bachmann et al. 2009; Machado-Vieira et al. 2009; Vernon et al. 2012).”
BackgroundLeucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 1×
“As employed in the MTM of antipsychotics in patients with schizophrenia (Leucht et al. 2013), we performed several post-hoc sensitivity analyses on the primary outcome.”
MethodChecking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 2×
“We assessed network consistency by testing agreement between direct and indirect evidence for each pair of drugs with both direct and indirect evidence (Dias et al. 2010).”
MethodMerikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399 · cited 2×
“5% (Merikangas et al. 2007).”
BackgroundInfluential
Research works printed but not linked: 3
- Kriston, Bipolar Book: History, Neurobiology, and Treatment
- Lerer, 1987, Carbamazepine vs. lithium in mania: double-blind study, Journal of Clinical Psychiatry, 48, 89
- Ortega Soto, 1993, Carbamazepine vs haloperidol in treatment of manic episodes: controlled clinical trial, (Spanish) Salud Mental, 16, 44
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
“Antimanic efficacy has not been demonstrated for allopurinol (Level 1-ve)(168), eslicarbazepine/licarbazepine (Level 2-ve) (169), gabapentin (Level 2 -ve), lamotrigine (Level 1ve)(144), omega-3 fatty acids (Level 1-ve) (170), topiramate (Level 1-ve) (144), valnoctamide (Level 2 -ve) (171, 172), or zonisamide (Level 2…”
BackgroundSelf-citationGrande, I., Berk, M., Birmaher, B., & Vieta, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00241-x · Cited by 1,710
Self-citationGoodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
“The relative efficacy and acceptability of the treatments for mania has been analysed using network meta-analysis (Cipriani et al., 2011; Yildiz et al., 2015).”
Self-citationMcIntyre, R. S., Berk, M., Brietzke, E., Goldstein, B. I., López-Jaramillo, C., Kessing, L. V., Malhi, G. S., Nierenberg, A. A., Rosenblat, J. D., Majeed, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31544-0 · Cited by 1,047
Self-citationVieta, E., Berk, M., Schulze, T. G., Carvalho, A. F., Suppes, T., Calabrese, J. R., Gao, K., Miskowiak, K. W., & Grande, I. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.8 · Cited by 891
Self-citation
Metadata
- Authors
- Yildiz, A., Nikodem, M., Vieta, E., Correll, C. U., & Baldessarini, R. J.
- Affiliations
- AGH University of Krakow (PL)
- Massachusetts General Hospital (US)
- Zucker Hillside Hospital (US)
- Harvard University (US)
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2014-07-18
- Volume
- 45
- Issue
- 2
- Pages
- 299-317
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W2162319254
- Cited by
- 128
- References
- 73
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 12 · 2023: 9 · 2022: 25 · 2021: 14 · 2020: 14 · 2019: 10 · 2018: 6 · 2017: 8 · 2016: 9 · 2015: 10 · 2014: 1
- FWCI
- 7.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychological Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- bipolar mania, antimanic drugs, bipolar I disorder, antipsychotic drugs, mood stabilizers, atypical antipsychotics, valproic acid, risperidone, aripiprazole, olanzapine, quetiapine, haloperidol, treatment discontinuation, treatment efficacy
- MeSH terms
- Bayes Theorem, Bipolar Disorder, Humans, Patient Dropouts, Randomized Controlled Trials as Topic, Treatment Outcome, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. https://app.cochat.ai/papers/10.1017/s0033291714001305
- The paper
- Yildiz, A., Nikodem, M., Vieta, E., Correll, C. U., & Baldessarini, R. J. (2015). A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychological Medicine. https://doi.org/10.1017/s0033291714001305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.